MedTrace Logo

Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura

NCT03501251 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2018-08-14

No results posted yet for this study

Summary

The study rationale is to provide evidence on effective doses of moxidectin and/or moxidectin-albendazole in adolescents (16-18 years old) infected with Trichuris trichiura. The study will take place on Pemba Island, Tanzania.

Conditions

  • Trichuris Trichiura; Infection

Interventions

DRUG

Moxidectin 8mg

Participants will receive the tablet with clean water and a package of biscuits.

DRUG

Moxidectin 8 mg + albendazole 400 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 16 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 16 mg + albendazole 400 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 24 mg

Participants will receive the tablets with clean water and a package of biscuits.

DRUG

Moxidectin 24 mg + albendazole 400 mg

Participants will receive the tablets with clean water and a package of biscuits.

OTHER

Placebo

Participants will receive the tablet with clean water and a package of biscuits.

Sponsors & Collaborators

  • Public Health Laboratory Ivo de Carneri

    collaborator OTHER

  • Swiss Tropical & Public Health Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-03
Primary Completion
2018-08-11
Completion
2018-08-11

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03501251 on ClinicalTrials.gov